Clinical Trial Update: Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

This document reports a Phase 2/Phase 3 clinical trial evaluating conservative iron chelation as a disease-modifying strategy for amyotrophic lateral sclerosis.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Snippet

Sponsor: University Hospital, Lille | Conditions: Amyotrophic Lateral Sclerosis | Phase 2, Phase 3 | Status: COMPLETED